properties of the COVID-19 convalescent plasma
暂无分享,去创建一个
D. | S. Petrikov | V. Shustov | D. Logunov | I. Dolzhikova | E. | V. Ganchin | A. Gintsburg | M. Lundgren | A. Bulanov | E. Ladygina | K. Chirkova | A. Bazhenov | A. Kamalova | S. Volkov | N. Borovkova | N. Drozdova | A. Bogdanova | M. Godkov | A. Kostin | Shcheblyakov | Dombrovskiy
[1] G. Guyatt,et al. A living WHO guideline on drugs for covid-19 , 2020, BMJ.
[2] M. Germain,et al. Risk of transmission of severe acute respiratory syndrome coronavirus 2 by transfusion: A literature review , 2020, Transfusion.
[3] W. D. dos Santos,et al. Natural history of COVID-19 and current knowledge on treatment therapeutic options , 2020, Biomedicine & Pharmacotherapy.
[4] A. Pennica,et al. Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review , 2020, SN Comprehensive Clinical Medicine.
[5] Fang Li,et al. Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.
[6] R. Bowen,et al. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light , 2020, bioRxiv.
[7] Y. Shoenfeld,et al. Convalescent plasma in Covid-19: Possible mechanisms of action , 2020, Autoimmunity Reviews.
[8] J. Epstein,et al. Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma , 2020, Vox sanguinis.
[9] P. Gallian,et al. Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how? , 2020, Vox sanguinis.
[10] C. Hillyer,et al. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.
[11] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[12] Yuan Shi,et al. Convalescent plasma as a potential therapy for COVID-19 , 2020, The Lancet Infectious Diseases.
[13] W. Handke,et al. Inactivation of three emerging viruses – severe acute respiratory syndrome coronavirus, Crimean–Congo haemorrhagic fever virus and Nipah virus – in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light , 2020, Vox sanguinis.
[14] G. Damanhouri,et al. Amotosalen and ultraviolet A light efficiently inactivate MERS‐coronavirus in human platelet concentrates , 2019, Transfusion medicine.
[15] W. Handke,et al. Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively , 2018, Transfusion.
[16] A. Hassan,et al. Inactivation of Middle East respiratory syndrome‐coronavirus in human plasma using amotosalen and ultraviolet A light , 2017, Transfusion.
[17] A. Cicchetti,et al. Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use. , 2016, Blood transfusion = Trasfusione del sangue.
[18] W. Lim,et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.
[19] Kwok-Hung Chan,et al. Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] S. Hoffman,et al. Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? , 2006, Annals of Internal Medicine.
[21] U. Sugg,et al. Transfusion Transmitted Infections , 1992 .